Spanish Red Biotech Pipeline 2016

Spanish Red Biotech Pipeline
Spanish Red Biotech Pipeline 2016
DRUGS: MULTINATIONAL SUBSIDIARIES **
D R UGS: M U LT INAT IONAL S U B SIDIA R IES
50%
15%
11%
12%
8%
6%
4%
3%
Inf
ec
ndo tions
Aut Lym crin
ol
oim
p
mu hatic ogy
ne
s
& I ystem
nfla
s
mm
atio
n
Can
cer
tem
/E
olic
lN
Car
dio
vas
Blo
od
Me
tab
tra
and
Sys
em
erv
ous
yst
rs
ys
rde
tor
iso
circ
ula
lD
eta
kel
and
los
cul
ar
Cen
ive
Mu
scu
Dig
est
rm
ato
Sys
log
th
eal
De
sh
ers
en
Oth
tem
1%
1%
Wo
m
4%
4%
Product
IFN 1a pgilated
BG-12
Aubagio (teriflunomida)
Nonacog beta pegol
Humira (adalimumab)
ABT-SLV187
Talimogene laherparepvec
Cinacalcet
Evolocumab
Alemtuzumab
Eliglustat
Liraglutide 3mg
Evofosfamida
Faster-acting insulin aspart (FIAsp)
IDegAsp (combination insulin degludec + insulin aspart)
IDegLira (combination insulin degludec + liraglutide)
Pimasertib
ISTODAX (romidepsin)
Ozanimod
Veliparib
Daclizumab
Avelumab
Doravirine
Elbasvir/Grazoprevir
Etonogestrel+ Estradiol (vaginal ring)
Pembrolizumab
TASELISIB
KADCYLA
MABTHERA
Elagolix
HCV Interferon-Free Combination (genotype 1)
ABT-981
Blinatumomab
Trebananib
Rilotumumab
CC 486
REVLIMID (lenalidomide)
AG-221
Mongersen (GED 0301)
ABRAXANE
Pembrolizumab
Odanacatib
Fosaprepitant
Pembrolizumab
Pembrolizumab
Inhibitor of human _-site APP cleaving enzyme (BACE1)
Pembrolizumab
Pembrolizumab
Anacetrapib
Semaglutide
Oral semaglutide
PDL1 MAB
AVASTIN
TAMIFLU
ONARTUZUMAB
AVASTIN
ONARTUZUMAB
ETROLIZUMAB
PDL1 MAB
XELODA
PERJETA
PERJETA
PERJETA
ALECTINIB
OCRELIZUMAB
MABTHERA
OCRELIZUMAB
OCRELIZUMAB
Pembrolizumab
Pembrolizumab
Somapacitan(Long-acting growth hormone)
GAZYVA
GAZYVA
Atrasentan
ABT-199/GDC0199
Etelcalcetide
Romosozumab
Denosumab
Brodalumab
Brodalumab
Darbepoetin alfa
REVLIMID (lenalidomide)
CC 486
OTEZLA (Apremilast)
Luspatercept (ACE-536)
Emtricitabine/Tenofovir alafenamide FDC
Emtricitabine/Rilpivirine /Tenofovir alafenamide STR
Emtricitabine/Tenofovir alafenamide FDC
Elvitegravir/Cobicistat /Emtricitabine/Tenofovir alafenamide STR
Momelotinib
Ranolazine
Idelalisib
Pembrolizumab
Letermovir
Inactivated VZV Vaccine
V920
Pembrolizumab
Pembrolizumab
Gardasil 9
Pembrolizumab
Gardasil 9
Pembrolizumab
Pembrolizumab
Pembrolizumab
Liraglutide
N8-GP (glycopegylated recombinant FVIII)
ALEGLITAZAR
TASPOGLUTIDE
COBIMETINIB
AVASTIN
VALCYTE
DALCETRAPIB
GANTENERUMAB
DALCETRAPIB
GAZYVA
ZELBORAF
HCV POL INH PRO
LAMPALIZUMAB
MABTHERA
GAZYVA
VENETOCLAX
MABTHERA
XOLAIR
MABTHERA
KADCYLA
ACTEMRA
BITOPERTIN
ACTEMRA
ACTEMRA
PEGASYS
ALEGLITAZAR
Cx601
CC-220
PDA-002
OI338GT (oral insulin)
AlloCSC-01
anti-TWEAK
antiLingo
Natalizumab
antiLingo
PD-L1 Inhibitor:durvalumab
PPM Pleiotropic Pathway Modifier: CC-122
Abituzumab
Atacicept
DULIGOTUZUMAB
ABT-414
ABT-494
Denosumab
Omecantiv mecarbil
Romiplostim
AMG 337
AMG 334
Conatumumab
AMG 181
CAR-T (JCAR15)
SOTATERCEPT (ACE-011)
Momelotinib
GS-4997 (ASK-1 inhibitor)
Simtuzumab
Simtuzumab
GS-5806 (fusion inhibitor)
GS-6615 (late sodium current inhibitor)
GS-4997 (ASK-1 inhibitor)
GS-5745 (MMP9 mAb inhibitor)
GS-5745 (MMP9 mAb inhibitor)
Pembrolizumab
Pembrolizumab
Pembrolizumab
Pembrolizumab
MK3682
Pembrolizumab
Pembrolizumab
Monoclonal antibody anti Il-21
TARCEVA
IPATASERTIB
ALPHA7 NIC AGO
DULIGOTUZUMAB
TARCEVA
IPATASERTIB
ANTI-INFLUENZA A
XELODA
KADCYLA
AVASTIN
EM ACTEMAB RA
ZELBORAF
LEBRIKIZUMAB
ERIVEDGE
GAZYVA
MERICITABINE
ERIVEDGE
GAZYVA
ONARTUZUMAB
ERIVEDGE
GPC3 MAB
ONARTUZUMAB
FORTOVASE
HPV16 TI
PARSATUZUMAB
HERCEPTIN
IGF1R MAB
PDL1 MAB
APITOLISIB
LIFASTUZUMAB VEDOTIN
IGF1R MAB
PICTILISIB
BASIMGLURANT
NEORECORMON
IMGATUZUMAB
PICTILISIB
CMV ANTI
PATECLIZUMAB
IMGATUZUMAB
SEMBRAGILINE
CRENEZUMAB
POLATUZUMAB VEDOTIN
IPATASERTIB
VANUCIZUMAB
DANOPREVIR
Cx611
Cx611
ABBV-838
ABBV-221
ABV-085
CC-90001
PNK-007
CC-122
AG-120
Pembrolizumab
Pembrolizumab
Pembrolizumab
Pembrolizumab
BET Inhibitor
Prandial Bioedge
OI320GT (oral insulin)
AM833 (amilyn analogue)
G53L (glucagon analogue/liraglutide)
PYY1562 (analogue peptid YY)
Insulin LA287
Semaglutide NASH
Prandial Bioedge
Concizumab
Prandial Bioedge
Prandial Bioedge
Prandial Bioedge
Prandial Bioedge
PDL1 MAB
COBIMETINIB
TASELISIB
COBIMETINIB
VANUCIZUMAB
DULIGOTUZUMAB
VENETOCLAX
EM RA PRED DEV
CD40 IMAB
ETROLIZUMAB
CEA CD3 TCB
IMGATUZUMAB
CIF MEK INH
IMGATUZUMAB
EM MS BIOMARKER
IPATASERTIB
LIFASTUZUMAB VEDOTIN
LUMRETUZUMAB
OX40
APITOLISIB
LUMRETUZUMAB
PLGF MAB
APITOLISIB
LUMRETUZUMAB
BRAF KIN INH (2)
PDL1 MAB
CEA IL2V
Cx621
Type
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Vaccines
Vaccines
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Gene / Cell Therapy
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Gene / Cell Therapy
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Gene / Cell Therapy
Gene / Cell Therapy
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Gene / Cell Therapy
Therapeutic Area
Autoimmune & Inflammation / Central Nervous System
Blood and Lymphatic systems
Autoimmune & Inflammation
Central Nervous System
Cancer
Autoimmune & Inflammation / Kidney and Genitourinary system
Cardiovascular and circulatory systems / Metabolic / Endocrinology
Genetic Diseases and Dysmorphic syndromes / Metabolic / Endocrinology
Metabolic / Endocrinology
Cancer / Dermatology / Digestive System
Cancer
Cancer
Cancer
Infections
Infections
Womens health
Cancer
Cancer
Cancer
Blood and Lymphatic systems / Cancer
Womens health
Infections
Analgesia & Pain / Autoimmune & Inflammation
Cancer
Cancer
Autoimmune & Inflammation / Digestive System
Cancer
Cancer
Musculoskeletal Disorders / Womens health
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Infections
Cancer
Cancer
Cancer
Autoimmune & Inflammation / Musculoskeletal Disorders
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Kidney and Genitourinary system
Musculoskeletal Disorders / Womens health
Musculoskeletal Disorders
Autoimmune & Inflammation / Dermatology
Infections
Infections
Infections
Infections
Cardiovascular and circulatory systems
Cancer
Infections
Infections
Cancer
Cancer
Infections
Cancer
Infections
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Infections
Ophthalmology and optometry
Cancer
Infections
Others
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Digestive System
Digestive System
Respiratory and Pulmonary system
Infections / Respiratory and Pulmonary system
Cancer
Cancer
Cancer
Cancer
Cancer
Infections
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Infections
Cancer
Cancer
Cancer
Cancer
Cancer
Infections
Cancer
Cancer
Cancer
Autoimmune & Inflammation / Cancer
Cancer
Cancer
Infections
Infections
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Genetic Diseases and Dysmorphic syndromes
Cancer
Cancer
Infections
Cancer
Cancer
Cancer
Infections
Autoimmune & Inflammation / Infections
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Indication
Multiple Sclerosis
Multiple Sclerosis
Multiple Sclerosis
Haemophilia B
Hidradenitis Suppurativa / Peripheral Spondyloarthritis / Uveitis / Ulcerative colitis / Chron Disease / Enthesitis paediatric / AR / Psoriasis
Parkinson
Malignant melanoma
Secondary hyperparathyroidism / Reducation of hypercalcaemia in patinents with parathyroid carcinoma or primary HPT
Hypercholesterolemia, mixed dyslipidemia and Homozygous familial hypercholesterolemia
Multiple Sclerosis
Lysosomal Diseases; Gaucher Disease
Obesity
Pancreas, cancer, sarcoma
Diabetes type 1 and type 2
Diabetes type 2 and type 1
Diabetes type 2
Colorectal Cancer, Pancreas, Melanoma, solid tumours and ovarian cancer
Peripheral T-cell lymphoma:First-line
Ulcerative colitis Crohn`s disease Relapsing multiple sclerosis
Brain cancer, Breast, ovarian and colorectal Cancer, Non-small-cell lung carcinoma (NSCLC)and Small Cell Lung Cancer (SCLC ), Triple-negative breast cancer (TNBC), solid tumors
Multiple Sclerosis
Several types of cancer
HIV Infection
Chronic Haepatitis C
Contraception
Pembrolizumab in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects
Malignant neoplasm of breast
Lymphoid leukaemia
Endometriosis
Haepatitis C
Knee Osteoarthritis
Acute lymphoblastic leukaemia
Ovarian Cancer
Various cancer types
Post-induction acute myeloid laeukemia (AML) maintenance Breast:Metastatic Nasopharyngueal carcinomal Non-small cell lung:Advanced
Diffuse large B -cell:Maintenance Diffuse large B -cell (ABC-subtype):First line Follicular lymphoma:First line Adult T-cell leukemia lymphoma Maintenance: Second-line Indolent lymphoma: Relapsed/ refractory
AML
Crohns disease Ulcerative colitis
Breast: Metastatic (1st-line, triple negative) locally advanced Pancreatic Cancer Lung cancer squamous Lung Cancer non squamous Pancreatic:Adjuvant
MSI-H or dMMR Stage IV Colorectal Carcinoma (1st line)
Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium
Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Patients with a histologically confirmed diagnosis of melanoma (MEL) with unresectable or metastatic disease that have not received ipilimumab (IPI) treatment
Subjects with histologically confirmed diagnosis of melanoma with unresectable or metastatic melanoma
Alzheimers Disease
Recurrent or Progressive Metastatic Urothelial Cancer
Metastatic Triple-Negative Breast Cancer (mTNBC)
Coronary Heart Disease (CHD) or CHD Risk- Equivalent Disease
Diabetes type 2
Diabetes type 2
Malignant neoplasm of bronchus and lung
Malignant neoplasm of brain
Influenza
Malignant neoplasm of ovary
Malignant neoplasm of stomach
Irritable bowel syndrome
Malignant neoplasm of bladder
Malignant neoplasm of colon/rectum
Rheumatoid arthritis
Other + unspecif. types of non-Hodgkins lymphoma
Systemic lupus erythematosus
Lenalidomide and low dose dexamethasone with Pembrolizumab in Newly diagnosed and treated naive Multiple Myeloma
Pomalidomide and low dose dexamethasone with pembrolizumab in refractory or relapsed Multiple Myeloma
Growth hormone deficiency
Follicular (nodular) non-Hodgkins lymphoma
Lymphoid leukaemia
Diabetic Nephropathy
Multiple mieloma
Secondary Hyperparathyroidism
Postmenopausal osteoporosis
Osteoporosis in postmenopausal women / Treatment of bone loss associated with hormone ablation in men with prostate cancer
Psoriatic arthritis
Psoriasis
Treatment of symptomatic anemia associated with chronic renal failure in adults / Treatment of symptomatic anemia in adult cancer patients with non-myeloid malignancies
Lymphoma Diffuse large B-cell
Myelodysplastic syndrome (MDS) Lower-risk MDS Post hypomethylating (HMA) failure
Ankylosing spondylitis Atopic dermatitis Ulcerative colitis Behcets disease
MDS
Chronic HBV infection
HIV/AIDS
HIV/AIDS
HIV/AIDS
Myelofibrosis
Incomplete revascularization post-PCI (Percutaneous Coronary Intervention)
Frontline chronic lymphocytic laeukemia, frontline/indolent non-Hodgkins lymphoma, relapsed refractory CLL
Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have progressed after First Line Standard Therapy
Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients
Adult Patients with Solid Tumor or Hematologic Malignancy
Three consistency lot doses and high dose of rVSV-ZEBOV-GiP (V920 ebola vaccine) in Healthy Adults
Pembrolizumab versus standard Treatment in subjects with recurrent or metastatic Head and Neck Cancer
First line treatment of recurrent/Metastasic Head and Neck Squamous Cell Carcinoma
V503 in Preadolescents and Adolescents (9 to 15 year olds) with a Comparison to Young Women (16 to 26 year olds)
Pembrolizumab in subjects with relapsed or refractory classical Hodgkin Lymphoma
2-dose regimen of V503, administered in Preadolescents and Adolescents (9 to 14 year olds) with a Comparison to Young Women (16 to 26 year olds)
PD-L1 Strong Metastatic Non-Small Cell Lung Cancer
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma First line
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma after First Line Progression
Diabetes type 2 in paediatric population
Haemophilia A
Diabetes Mellitus
Diabetes Mellitus
Malignant melanoma of skin
Transplanted organ and tissue status (Excl. complications)
Acute myocardial infarction
Alzheimers disease
Atherosclerosis
Diffuse non-Hodgkins lymphoma, unspecified
Malignant neoplasms
Chronic viral haepatitis
Retinal disorders other
Other necrotizing vasculopathies
Malignant neoplasms of lymphoid haematopoietic +
Lymphoid leukaemia
Pemphigus
Dermatitis (Allergic Contact)
Other disorders involving the immune mechanism
Schizophrenia
Peripheral Vascular Diseases
Thyrotoxicosis (hyperthyroidism)
Atherosclerosis
Perianal fistula in Crohn disease patients
Systemic lupus erythematosus
Peripheral artery disease/Diabetic foot ulcers Diabetic peripheral neuropathy
Diabetes type 1 and 2
Acute myocardial infarction
Lupus Nephritis
Multiple Sclerosis
Secondary Progressive Multiple Sclerosis
Optic Neuritis
Multiple Myeloma Myelodysplastic Syndromes Acute Myeloid Leukemia (AML) Chronic Lymphocytic Leukemia Lymphoma
Gliobastoma Multiforme Hepatocellular carcinoma
Colorectal Cancer, Prostate cancer, solid tumours
Autoinmune disease
Malignant neoplasms
Relapsed GBM / Incipient GBM
Rheumatoid Arthritis, Crohn Disease
Giant cell tumour of the bone
Heart failure
Adult chronic - immune (idiopatic)-thrombocytopenic-purpura (ITP)
Gastric cancer
Migraine
Various cancer types
Crohns disease
ALL( Accute Lymphoblastic Leukemia)
Chronic kidney disease
Pancreatic cancer
Nonalcoholic steatohaepatitis
Liver fibrosis, primary sclerosing cholangitis, nonalcoholic steatohaepatitis
Idiopathic pulmonary fibrosis
Respiratory syncytial virus
Ventricular tachycardia / Ventricular fibrillation
Pulmonary arterial hypertension
Ulcerative colitis
Solid tumors
Advanced/Unresectable or Metastatic Urothelial Cancer
MSI-H or dMMR Stage IV Colorectal Carcinoma (after progression of First and second line Standard Therapy)
Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC)
Pembrolizumab in Previously Treated Subjects with Squamous Histology Non-Small Cell Lung Cancer
Chronic Haepatitis C
Pembrolizumab in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)
Pembrolizumab in subjects with recurrent ovarian cancer
Diabetes type 1
Malignant neoplasm of other and ill-defined sites
Malignant neoplasm of prostate
Alzheimers disease
Malignant neoplasm of pancreas
Influenza
Malignant neoplasm of cervix uteri
Malignant neoplasm without specification of site
Other diseases of upper respiratory tract
Lymphoid leukaemia
Malignant neoplasm of other and unspecified parts of biliary tract
Malignant neoplasm of brain
Other disorders involving the immune mechanism
Malignant neoplasm of liver
HIV disease unspecified
Viral agents as cause of diseases classified to other
Malignant neoplasm of bladder
Malignant neoplasm of kidney except renal pelvis
Malignant neoplasm of kidney except renal pelvis
Malignant neoplasms
Fragile X Syndrome
Anaemia in neoplastic disease
Cytomegaloviral disease
Alzheimers disease
Alzheimers disease
Follicular (nodular) non-Hodgkins lymphoma
Severe sepsis
Multiple myeloma
EGFR (Epidermal growth factor receptor)
Solid tumor
Fibrosis
AML
Diffuse large B-Cell
AML
20 Select Advanced Solid Tumors
In combination with Chemotherapy as Neoadjuvant Treatment for Triple Negative Breast Cancer (TNBC)
Pembrolizumab in combination with lenalidomide and dexamethasone in subjects Multiple Myeloma
Obesity
Obesity
Obesity
Non-alcoholic steatoHaepatitis
Haemophilia A and B
Malignant neoplasms
Malignant neoplasms
Malignant neoplasms
Other malignant neoplasms of skin
Crohns disease
Malignant neoplasms
Crohns disease
Malignant neoplasms
Malignant neoplasms
Malignant neoplasms
Crohns disease
Malignant neoplasms
Malignant neoplasms
Malignant neoplasms
Malignant neoplasms
TBD (Tick-borne diseases)
Phase I
Phase II
Phase III
Registration
<<<<< <<<<< <<<<< <<<<<
<<<<< <<<<< <<<<< <<<<<
<<<<< <<<<< <<<<<
<<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<< <<<<< <<<<<
<<<<< <<<<< <<<<<
<<<<< <<<<< <<<<<
<<<<< <<<<< <<<<<
<<<<< <<<<< <<<<<
<<<<< <<<<< <<<<<
<<<<< <<<<< <<<<<
<<<<< <<<<< <<<<<
<<<<< <<<<< <<<<<
<<<<< <<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<< <<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<< <<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
RESEARCH PLATFORMS
www.asebio.com
Spanish Bioindustry Association
ASEBIO, the Spanish Bioindustry Association, encompasses over 280 firms, associations, foundations, universities, technology and
research centers which carry out activities directly or indirectly related to biotechnology.
The wide number of associates makes ASEBIO the most appropriate meeting platform to face up the challenges of developing the
biotechnology sector in Spain.
Around 630 companies research and develop products in the Spanish biotechnology sector.
Company
Biogen Spain
Biogen Spain
Genzyme
Novo Nordisk Pharma
AbbVie
AbbVie
Amgen
Amgen
Amgen
Genzyme
Genzyme
Novo Nordisk Pharma
Merck KGaA
Novo Nordisk Pharma
Novo Nordisk Pharma
Novo Nordisk Pharma
Merck KGaA
Celgene
Celgene
AbbVie
Biogen Spain
Merck KGaA
MSD
MSD
MSD
MSD
Roche
Roche
Roche
AbbVie
AbbVie
AbbVie
Amgen
Amgen
Amgen
Celgene
Celgene
Celgene
Celgene
Celgene
MSD
MSD
MSD
MSD
MSD
MSD
MSD
MSD
MSD
Novo Nordisk Pharma
Novo Nordisk Pharma
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
MSD
MSD
Novo Nordisk Pharma
Roche
Roche
AbbVie
AbbVie
Amgen
Amgen
Amgen
Amgen
Amgen
Amgen
Celgene
Celgene
Celgene
Celgene
Gilead Sciences
Gilead Sciences
Gilead Sciences
Gilead Sciences
Gilead Sciences
Gilead Sciences
Gilead Sciences
MSD
MSD
MSD
MSD
MSD
MSD
MSD
MSD
MSD
MSD
MSD
MSD
Novo Nordisk Pharma
Novo Nordisk Pharma
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
TiGenix
Celgene
Celgene
Novo Nordisk Pharma
TiGenix
Biogen Spain
Biogen Spain
Biogen Spain
Biogen Spain
Celgene
Celgene
Merck KGaA
Merck KGaA
Roche
AbbVie
AbbVie
Amgen
Amgen
Amgen
Amgen
Amgen
Amgen
Amgen
Celgene
Celgene
Gilead Sciences
Gilead Sciences
Gilead Sciences
Gilead Sciences
Gilead Sciences
Gilead Sciences
Gilead Sciences
Gilead Sciences
Gilead Sciences
MSD
MSD
MSD
MSD
MSD
MSD
MSD
Novo Nordisk Pharma
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
TiGenix
TiGenix
AbbVie
AbbVie
AbbVie
Celgene
Celgene
Celgene
Celgene
MSD
MSD
MSD
MSD
MSD
Novo Nordisk Pharma
Novo Nordisk Pharma
Novo Nordisk Pharma
Novo Nordisk Pharma
Novo Nordisk Pharma
Novo Nordisk Pharma
Novo Nordisk Pharma
Novo Nordisk Pharma
Novo Nordisk Pharma
Novo Nordisk Pharma
Novo Nordisk Pharma
Novo Nordisk Pharma
Novo Nordisk Pharma
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
Roche
TiGenix
Company
Type
Description
3P BIOPHARMACEUTICALS
AC-Gen Reading Life
AC-Gen Reading Life
Bionaturis
BIOPOLIS
BIOPOLIS
BIOPOLIS
CIBER/CIBER-BBN
CIBER/CIBER-BBN
FUND. PROGRESO Y SALUD (BIONAND)
Gadea Biopharma
Health in Code
Histocell
Ingeniatrics
Iproteos
Leitat
Leitat
Leitat
Leitat
OWL Metabolomics
Plebiotic
SISTEMAS GENMICOS
SISTEMAS GENMICOS
StemTek Therapeutics
Vivia Biotech
Bionanoplus
ASCIL Biopharm
ASCIL Biopharm
Bionanoplus
Bionanoplus
FUND. PROGRESO Y SALUD (IATA)
Fundacion MEDINA
Fundacion MEDINA
Fundacion MEDINA
Fundacion MEDINA
Fundacion MEDINA
Fundacion MEDINA
IRYCIS
Lipopharma Therapeutics
OPERON
ASCIL Biopharm
ASCIL Biopharm
ASCIL Biopharm
Bionanoplus
Bionanoplus
CIBER/CIBER-BBN
CIBER/CIBER-BBN
FUND. PROGRESO Y SALUD (OTT-SSPA-FISEVI/IBIS)(SAS)
Fundacion MEDINA
IMMUNOSTEP
Ingeniatrics
Ingeniatrics
Ingeniatrics
Minoryx
Neuron Bio
Plebiotic
AC-Gen Reading Life
ASCIL Biopharm
ASCIL Biopharm
BIOPOLIS
BIOPOLIS
CIBER/CIBER-BBN
Enzymlogic
Enzymlogic
FUND. PROGRESO Y SALUD (BIONAND)
FUND. PROGRESO Y SALUD (CABIMER)
FUND. PROGRESO Y SALUD (CABIMER)
FUND.Progreso y salud/ OTT (SAS)
FUND.Progreso y salud/ OTT (SAS)
Fundacion MEDINA
IMEGEN
Ingeniatrics
InKemia IUCT group
InKemia IUCT group
InKemia IUCT group
Integromics
Plebiotic
VIVEBIOTECH
Vytrus Biotech
CRO / CMO
CRO / CMO
CRO / CMO
CRO / CMO
CRO / CMO
CRO / CMO
CRO / CMO
CRO / CMO
CRO / CMO
CRO / CMO
CRO / CMO
CRO / CMO
Screening
Screening
CRO / CMO
CRO / CMO
CRO / CMO
CRO / CMO / Screening
CRO / CMO / Enabling Technologies / Others
CRO / CMO / Enabling Technologies / Others
CRO / CMO
Screening
CRO / CMO
Drug Delivery
Enabling Technologies / Screening
CRO / CMO / Enabling Technologies / Screening
Screening
Screening
Screening
Screening
Screening
Drug Delivery
Drug Delivery / Enabling Technologies
Drug Delivery
Drug Delivery
CRO / CMO
CRO / CMO
CRO / CMO
CRO / CMO
Screening
Screening
CRO / CMO
Others / Screening
Enabling Technologies
Screening
Drug Delivery
Drug Delivery
Drug Delivery
CRO / CMO / Enabling Technologies
Screening
Screening
Screening
Drug Delivery
Drug Delivery
Screening
Screening
Drug Delivery
Drug Delivery
CRO / CMO
Enabling Technologies / Others
Drug Delivery
FIBAO-14014
FIBAO-13036
Enabling Technologies / Screening
Screening
Drug Delivery
CRO / CMO
CRO / CMO
CRO / CMO
Screening
CRO / CMO
CRO / CMO
Freedom-to-operate platform in Bacteria, yeast and mammalian

Production of advanced Therapy Medicinal Products
API/IMP release
Biologics production: New Biological Entities (mAbs, vaccines, fusion proteins) and Biosimilars/Biobetters from microbial fermentation and mammalian cell culture
Development of API formulation
Stability Studies (API/IMP/Cell banks)
GMP Cell Bank Manufacturing (MCB/WCB/EPCB) and storage
GMP production (fermenters up to 1000L and Bioreactors up to 400L) for Clinical trials and Commercial stage
Scale up and No GMP production for Preclinical studies
Analytics development and validation platform (API, IMP, IPC) for Biosimilars
Analytics development and validation platform (API, IMP, IPC) for New biological entities
Bioprocess Development/Optimization Platform (USP/DSP)
Phatogenomics
NGS, Sequence Capture; Genetic Diseases and Dysmorphic syndromes; Exome Analysis, Genomics, infections
Development and manufacturing of recombinant proteins by means of FLYLIFE technology
Contract manufacturing: upstream and downstream development, analytical development, scale-up
Metagenomics and metabolomic analysis
Preclinical validation platforms: C.elegans model for functional food, ingredients and drug trials
Production of Customized Biomaterials, Nanomaterials & Nanoconjugates
Production of Customized Biomolecules (Antibodies, Proteins and Peptides)
Genomics and Bioinformatic Platform of Andalusia / Nanoimaging & Metabolomic platform / Biobank
Industrial fermentation and downstream
Next Generation Sequencing by HiSeq 1500
Cell shipping medium. To develop ready-to-use cell based models for research
Process and technologies for customized Drug Delivery Formulations
IPRO Technology is a platform for the discovery and development of peptidomimetics able to disrupt and/or modulate protein-protein or protein-ligand interactions
In vivo animal model platform (Oncology, Angiogenesis, Efficacy, pre-Tox, Biodistribution, pre-Pk, Drug Reprofiling) Syngenic & xenogenic, Subcutaneous & orthotopic, Experimental & spontaneous metastasis, Patient Derived Orthotopic Xenografts (PDX, avata
In vitro cellular models platform (Efficacy, pre-Tox, Mechanism of Action, Drug Reprofiling) Proliferation, Viability, Apoptosis, Migration, Wound Healing, Adhesion, Angiogenesis, Tumorspheres (CSC), ADCC, CDC...
Polyclonal & Monoclonal Antibody Generation and Production Platform Recombinant proteins, Immunization, Serum title, Mouse polyclonals, Fusion, Screening, Cloning, Hybridomas, Isotyping, Production & Purification, F(ab)2, Fab, scFv, Conjugation, ELISA,
Antibody & Protein Engineering Platform: Cloning, Chimeric mAbs, Humanized mAbs, scFv fragments, Fusion proteins Modeling, Transient expression, Stable clones, Nanobodies, Bispecifics, ADCs, Production, Biosimilars
Lipidomics Platform
Molecular Dynamics product v2 (PleMD v2.0)
Whole exome resequencing in humans permits the identification of the new genes associated with both rare and common diseases
Pharmacogenomics. Markers of drug response
Drug screening / Discovery / validation on cancer stem cells, phenotypic HTS screening, secondary validation to in vivo efficacy testing
Cytometry Analysis for Personalized Medicine/Diagnosis/Pharma Profiling. Drug profiling and biomarker discovery collaborations
NANO-GES: drug delivery using polymeric encapsulation with esters of poly (methyl vinyl ether-co-maleic anhydride) PCT/EP2012/056900
ASRET Platform: Biomedical devices for implantable systems administration
ASMEX Platform: Safety syringes alternatives-prefilled ready to use medical devices for parenteral administration/syringes or cartridge
MUCO-LAST Technology: Compositions for mucosal adhesion and uses thereof. Intelectual property rights until 2036 (PATENT: EP16382136).
SANP: drug delivery using polimeric encapsulation with a vegetable hydrophobic protein PCT/EP2013/052795
Maturing technological platform in advanced therapies: setting up and monitoring of clinical trials
Bioanalytical Platform
Chemical Isolation & Structural Elucidation
Microbial and Mammalian cell culturing
Microbial Natural Product Libraries
High throughput screening platform for drug discovery
Preclinical Safety Platform
miRNA platform to collaborate in the development and commercialization of new biomarkers for diagnosis, prognosis and drug response
A novel therapeutic approach: Membrane Lipid Therapy (MLT)
Opegen S.pneumoniae: Molecular test for the genotyping of Streptococcus pneumoniae infections
ASTECH Platform: Optimized presentation and technologies for freeze-dried drug product and formulation-prefilled system. Improvement of FD for injectables products
ASTIC Platform: Implantable biodegradable systems and medical devices for administration. From daily to semi-annual delivery of biologics or pharma drugs. Micro/nanoimplantable solid system.
ASMAT Platform: New semisolid Biodegradable biomaterials for controlled release applications
Polymeric nanoemulsion technology for topical application
Antigen delivery for vaccines. Encapsulation of antigens with a polymer to increases the vaccination efficacy
Preclinical Validation-Bioimaging. Integrated Infrastructure on Production and characterization of Nanomaterials, Biomaterials and systems in Biomedicine
Preclinical Validation-Tissue, Biomaterial and Surface Characterization
Cell lines & Animal Models
High throughput screening platform for drug discovery
Reagents, columns and devices for Cell separation in Blood and Lymphatic systems
Platform for highthroughput analysis of microorganisms. Accelerated diagnosis of bacterial diseases. Several
Platform for coating of Medical Devices. Odontology
Pneumo: New European research project aims to tackle antibiotic resistance issue raised by WHO via inhalable nanotherapeutics
SEE-Tx: Site-directed Enzyme Enhancement Therapy
Drug discovery and development activities focused on neurodegenerative diseases, inflammatory processes and hypercholesterolemic conditions (HTS preclinical platform)
Novel software for molecular design of antibodies, based on molecular dynamics
Phatogenomis
ASLINX Platform: Parenteral controlled release liquid technology based on Inherent characteristics of the API
ASEM Platform: Parenteral controlled release technology built specifically around inherent characteristics of the API to get an optimal PK/PD with or without excipients
Novel functional probiotics screening, validation and production
Recombinant protein expression systems
High Performance Computing. Integrated Infrastructure on Production and characterization of Nanomaterials, Biomaterials and systems in Biomedicine
Development of an assay platform to perform binding kinetic profiling of GPCR agonist and antagonist in a HTS format
Development of an assay platform to perform binding kinetic profiling of KINASE inhibitors in a HTS format
Liposome delivery System (Prostate Cancer)
Cancer Screening Cell lines & Animal Models
Hybridome/Antibody Production Platform
Cell culture/Cancer
Biomaterials
Mass spectrometry metabolomics
Whole exome sequencing
Method for producing elongatedd structures such as fibers from polymer solutions by straining flow spinning
Drug development platform: Galenic development (Pre-formulation studies , Formulations development, Formulations Optimization, Stability Formulations, Comparison of dissolution profiles, Batch Productions at pilot levels, Support in technological transfer
Drug development platform: GMP Manufacturing of investigational drugs; Production of solid, semisolid and liquid (non-sterile) pharmaceutical products, Production of medicinal products under research and veterinary medicinal products, Support in studies f
Drug development platform: Stability studies under ICH conditions (Product storage according to ICH regulations, Product testing, Development of study protocol, Preparation for the study report)
Genomics Analysis for Personalized Medicine/Diagnosis
Novel reverse docking software, for repositioning purposes
Production of viral vectors deriving from lentivirus, adenovirus, and adeno-associated virus (UNE-EN ISO 9001:2008) providing services to academic researchers and industry for in vitro and in vivo research studies.
Development and manufacturing of recombinant proteins through the technology of plant cell cultures
* Based on data provided by ASEBIO members. MAY 2016. ** Only coloured phases have been developed in Spain
www.asebio.com
R+D
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
Preliminary
Validation
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
Clinical
Validation
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
Register
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
Ready To
Market
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
Spanish Red Biotech Pipeline
Spanish Red Biotech Pipeline 2016
DRUGS: NATIONAL COMPANIES
D R U G S : NAT IONAL C OM P A NIES

35%
Company
Product
Type
Almirall
Bionanoplus
Stem Center S.L.U.
VENTER PHARMA
Almirall
FERRER
NATAC
PharmaMar
PharmaMar
PRAXIS
PRAXIS
Reig Jofr
Ability Pharmaceuticals
Almirall
Almirall
Araclon Biotech
Archivel Farma
ESTEVE
ESTEVE
FERRER
FUND. PROGRESO Y SALUD / IATA (SAS)
FUND. PROGRESO Y SALUD / OTT (SAS)
GP-PHARM
PharmaMar
PharmaMar
PharmaMar
PharmaMar
PharmaMar
SOM Biotech
SOM Biotech
SPHERIUM BIOMED S.L
SPHERIUM BIOMED S.L
Sylentis
Sylentis
Thrombotargets
Almirall
Bionure
FERRER
Genmedica Therapeutics
GP-PHARM
GP-PHARM
GP-PHARM
GP-PHARM
GP-PHARM
GP-PHARM
Histocell
Histocell
Minoryx
Oryzon
Oryzon
PaloBiofarma
PaloBiofarma
PharmaMar
PharmaMar
VCN Biosciences
Ability Pharmaceuticals
Bioibrica S.A.
Bionanoplus
Bionaturis
Bioncotech Therapeutics
DIOMUNE SL
ENTRECHEM
ENTRECHEM
ENTRECHEM
ENTRECHEM
ENTRECHEM
ENTRECHEM
ESTEVE
ESTEVE
FECYT
FECYT
FECYT
FERRER
FIBROSTATIN
Formune SL
FUNDACIN JIMNEZ DAZ
(Instituto de Investigacin Sanitaria)
FUNDACIN JIMNEZ DAZ
(Instituto de Investigacin Sanitaria)
GP-PHARM
Histocell
Neuron Bio
nLife Therapeutics, S.L.
PaloBiofarma
PaloBiofarma
Pevesa
PRAXIS
SPHERIUM BIOMED S.L
Sylentis
Sylentis
TERACLON IDF
TERACLON IDF
VIVEBIOTECH
Vivia Biotech
LAS 40464 (aclidinium bromide + formoterol)

Propylene Glycol Free Minoxidil Topical Formulation
GID SVF-1
LacTEST
LAS 41008
Ozenoxacin
Retriacyl
PM01183
Aplidin
BERENICE
EPIPROT
Bioadhesive topical gel
ABTL0812
LAS 41004
LAS 100977
ABvac40
RUTI
E-52862
E-58425
Lorediplon
Engineered Corneas
Autologous Bone Marrow progenitors, Adipose and Bone Marrow Mesenchymal stem cells
Autologous Bone Marrow Mononuclear cells and Adipose Mesenchymal stem cells
Autologous Bone Marrow Mononuclear cells
Allogeneic Adipose Mesenchymal stem cells / Allodepleted Bone Marrow Progenitors
FIMABIS-14003
FIBAO-91 Melatonine Solution
Octeotride LAR
Minerval
PM01183
PM060184
Aplidin
Aplidin
PM01183
SOM3355
SOM0226
SP13004
SP12006
SYL1001
Bamosiran/SYL040012
TT-173
LAS 190972
BN201
FAB-117
Autologous Bone Marrow Mononuclear cells
FIBAO-13014 Combination of Ketamine and Meperidine
FIBAO-116
GMC-252
Triptorelina Depot 1-3
Octeotride MAR
Lutrate Depot 45 mg
Pegylated Liposomes for Oncology
depot form.
TERIPERATIDE
HR004
HC016
MIN-102
ORY-1001
ORY-2001
PBF-509
PBF680
PM060184
PM01183
VCN-01
ABTL1014
BIS014
Psorio-Plus spray and gel
BNT-001
BO-110
IV1303
EC-8042 iv for Ewing sarcoma
EC-8042 iv for Triple negative breast cancer
EC-70124 po for TNBC
EC-70124 po for prostate cancer
EC-8042 iv for liposarcoma
EC-70124 po for AML
MUMO1
EGT-101
Pylori
p300
p38
FAB-114
FSSME12
EDA-HPVE7
FIBAO-13007
FRM-5
FISEVI-13020
FISEVI 141
FISEVI-13002
FISEVI-121
FIMABIS-99
FIMABIS-13001
FIMABIS-77
FIMABIS-13007
FIMABIS-13007
FISEVI-14012
FISEVI-13007
FIBAO-15005
Biodrugs / Drugs
Biodrugs / Drugs
Gene / Cell Therapy
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Vaccines
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Gene / Cell Therapy
Gene / Cell Therapy
Gene / Cell Therapy
Gene / Cell Therapy
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Gene / Cell Therapy
Gene / Cell Therapy
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Gene / Cell Therapy
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Gene / Cell Therapy
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Vaccines
Gene / Cell Therapy
Gene / Cell Therapy
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Gene / Cell Therapy
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Gene / Cell Therapy
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Gene / Cell Therapy
Mutli-target siRNA approach

New generation of peptides
Risperidona Depot
HR017
LP226A1
NST0037
NLF-PD-1233
PBF-695
PBF-999
PEV pept. 01-02
OLEA
SP14019
siRNA
V32R
V-32-R
GMP-grade viral vectors
Vivia 009
12% 12%
11%
cer
Can
tem
sys
atio
lN
erv
ous
gy
mm
tra
&I
Cen
ne
mu
oim
Aut
tab
Me
Ge
net
ic D
ise
Op
nfla
olo
log
/E
ndo
ato
olic
gy
olo
alm
hth
crin
etr
rm
De
and
pha
Lym
and
od
Blo
s
opt
om
ion
ect
Inf
sys
tic
sia
tem
es
&P
ain
rom
Ana
rph
mo
Dys
nd
sa
10%
9%
8%
7%
lge
ic s
ynd
Oth
ers
7%
DI A GN O STI C S AND P E RS ONALIZ ED MEDIC INE

44%
21%
16%
13%
13%
9%
pha
tic
Lym
Dig
es
rom
ynd
cs
Blo
od
and
Ge
net
ic D
ise
ase
s
and
mo
rph
i
Dys
circ
ula
tor
ys
yst
em
ers
Oth
and
ar
cul
5%
sys
tem
s
est
Cen
ive
sys
tra
lN
tem
Aut
erv
oim
ous
mu
Sys
ne
tem
&I
nfla
mm
atio
n
Inf
ect
ion
s
Can
cer
5%
4%
dio
vas
Chronic complications of Diabetes
<<<<< <<<<<
Schizophrenia
Idiopathic Pulmonary Fibrosis
Alzheimers Disease
Mild Cognitive Impairment / Epilepsy
Parkinson Disease
Glaucoma
Huntington Disease
Metabolic Syndrome
Antiagins drugs and nutraceutics
Atopic Dermatitis & Psoriasis
Ocular Allergy
Crohns disease and ulcerative colitis
Diabetic Retinopathy
Glaucoma
Development of gene therapy products in strict compliance with requirements established under current legislation
Non Hodgkin Lymphoma, CNS
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
Regulatory
Preclinical
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
Phase I
Phase II
Phase III
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
Registration Studies location

<<<<<
<<<<<
<<<<<
<<<<<
Europe
Europe
Europe
Europe
Worldwide
Europe
Worldwide
Europe and South Africa
Europe
Europe
Europe
Europe
Europe
Europe
Worldwide
Worldwide
Worldwide
Worldwide
Europe
Europe
Europe
Europe and USA
Europe
Worldwide
Worldwide
Europe
Europe and Latinamerica
Worldwide
Worldwide
Worldwide
Europe
Europe
Europe
Europe
Europe
Europe
Europe
Europe
Europe
Europe
Europe
Europe
Europe
Europe
Europe
Europe
Europe
Worldwide
Worldwide
Europe
Europe
Europe
Europe and USA
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
Europe
Spain
Europe
DIAGNOSTICS AND PERSONALISED MEDICINE

20%
ase
Chronic obstructive pulmonary disease (COPD)

Hair Loss
Plastic and reconstructive surgery
Evaluation of hypolactasia
Psoriasis
Dermal infections
Retinitis Pigmentosa
Platinum-resistant ovarian cancer
Multiple Myeloma
Chagas
Diabetic Foot
Impetigo, skin infections
Lung, Endometrial and Pancreatic Cancer
Psoriasis
Asthma & COPD
Alzheimers Disease
Active tuberculosis - Latent Tuberculosis
Neuropathic Pain
Acute and chronic, moderate to severe pain
Sleep disorders
Corneal ulcers
Stroke, Multiple Sclerosis and ALS
Extended Liver resection, Faecal Incontinence
Acute Myocardial Infarction/Dilated Myocardiopathy/Chronic Ischemic Cardiopathy/Critical Limb Ischemia in diabetic & non patients
Chronic Graft versus Host Disease, Haematological Malignancies
Treatment of mucocutaneous herpes infections
Sepsis
Acromegaly
Glioma and other solid tumours
Breast cancer
Breast cancer
Multiple Myeloma in combination with bortezomid
T cell Lymphoma
Lung cancer
Huntingtons disease, Tourette syndrome and Tardive Dyskinesia
Transthyretin-related hereditary amyloidosis (Polyneuropathy, Cardiomyopathy and Senile Forms)
Prevention and treatment of radiochemotherapy-induced mucositis in head and neck cancer
Treatment of Temporomandibular Joint Disorder (TMJD)
Dry eye Syndrome
Ocular Hypertension, Glaucoma
Haemorrhage
Chronic obstructive pulmonary disease (COPD)
Acute Optic Neuritis, Neuromyelitis Optica, Multiple Sclerosis
Spinal Cord Injury
Critical Limb Ischemia in diabetic patients
Mucositis
Fibromyalgia
Type 2 Diabetes
Prostate Cancer
Acute diarrhoea post chemotherapy
Prostate Cancer
Advanced Ovarian Cancer, Advanced Breast Cancer
Several
Osteoporosis
Bone Regeneration
Neuroprotection & repair
X-linked Adrenoleukodystrophy
Acute Myeloid Leukaemia, Solid tumors, Other oncohaematology indications
Alzheimers disease, Parkinsons disease, other dementias, Huntingtons disease, Retts syndrome
Attention-Deficit, Hyperactivity Disorder (ADHD), Lung Cancer
Asthma
Solid tumours
Combination trials
Pancreatic cancer
Leukaemia and Lymphomas
Neuropathic pain
Help improving and soothing the manifestations of hyperkeratinized skins
Lysosomal storage diseases
Solid tumors
Sepsis treatment, Stroke, Rare diseases (CDH), Leishmania, ZIKV
Solid tumours
Triple negative breast cancer
Triple negative breast cancer
Castration resistant prostate cancer
liposarcoma myxoide
Acute myeloid leukemia
Acute and chronic, moderate to severe pain
Sanfilippo A syndrome:Lysosomal storage rare disease
H. pylori
Cancer
Neuropathic Pain
Non Hodgkin Lymphoma
Lung and Breast Cancer
Cervical cancer
Cancer cells
Transplant
Alzheimers disease
Sepsis, Acute lung injury
Multiple myeloma
Transplant
Nanoemulsions for the treatment of obesity
Treatment and/or Prevention of Non-alcoholic fatty liver disease (NAFLD)
Hydroxytyrosol ethers
Treatment and/or prevention of metabolic and cardiovascular diseases
Treatment and/or Prevention of cardiovascular and metabolic diseases
Multirresistant infections
Hepatocarcinoma
Tumors gastrointestinal mucosa
Diabetes type I & II
Obesity / Diabetes
Haepatitis C
Chronic Kidney Disease (CKD)/ Akute Kidney Injury (AKI)
Non
Regulatory
Preclinical
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
Indication

Dermatology
Others
Digestive System
Dermatology / Infections
Cancer
Cancer
Dermatology
Dermatology
Cancer
Infections
Analgesia & Pain
Analgesia & Pain
Digestive System
Autoimmune & Inflammation / Blood and Lymphatic systems
Dermatology / Infections
Infections
Cancer
Cancer
Cancer
Cancer
Cancer
Central Nervous System / Genetic Diseases and Dysmorphic syndromes
Central Nervous System / Genetic Diseases and Dysmorphic syndromes
Cancer / Dermatology / Digestive System
Analgesia & Pain / Musculoskeletal Disorders
Central Nervous System / Ophthalmology and optometry
Analgesia & Pain
Cancer
Cancer / Digestive System
Cancer
Cancer
Cancer
Central Nervous System / Metabolic / Endocrinology
Cancer / Central Nervous System
Cancer
Cancer
Cancer
Analgesia & Pain / Central Nervous System
Dermatology
Cancer
Autoimmune & Inflammation / Cardiovascular and circulatory systems / Genetic Diseases and Dysmorphic syndromes / Infections
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Analgesia & Pain
Infections
Cancer
Analgesia & Pain / Central Nervous System
Cancer
Cancer
Cancer
Others
Infections
Cancer
Infections
Cancer
Cancer
Infections
Autoimmune & Inflammation / Blood and Lymphatic systems / Cardiovascular and circulatory systems Kidney and Genitourinary
Biodrugs / Drugs
system / Metabolic / Endocrinology / Ophthalmology and optometry
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Dermatology
Biodrugs / Drugs
Dermatology
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Biodrugs / Drugs
Gene / Cell Therapy Genetic Diseases and Dysmorphic syndromes
Biodrugs / Drugs
Blood and Lymphatic systems / Central Nervous System
23%
Car
Therapeutic areas
www.asebio.com
Spanish Bioindustry Association
ASEBIO, the Spanish Bioindustry Association, encompasses over 280 firms, associations, foundations, universities, technology and
research centers which carry out activities directly or indirectly related to biotechnology.
The wide number of associates makes ASEBIO the most appropriate meeting platform to face up the challenges of developing the
biotechnology sector in Spain.
Around 630 companies research and develop products in the Spanish biotechnology sector.
Company
Product
Type
Therapeutic Area
Indication
AB-Biotics
AC-Gen Reading Life
AC-Gen Reading Life
AC-Gen Reading Life
AC-Gen Reading Life
AC-Gen Reading Life
AC-Gen Reading Life
AC-Gen Reading Life
AC-Gen Reading Life
Araclon Biotech
CYTOGNOS
FERRER
Fundacion MEDINA
Health in Code
IMEGEN
IRYCIS
Leitat
Life Length
Myriad Genetics
Neuron Bio
OPERON
OWL Diagnostics
OWL Metabolomics
OWL Metabolomics
OWL Metabolomics
SECUGEN
SECUGEN
SISTEMAS GENMICOS
SISTEMAS GENMICOS
SISTEMAS GENMICOS
SISTEMAS GENMICOS
SISTEMAS GENMICOS
SISTEMAS GENMICOS
SISTEMAS GENMICOS
SISTEMAS GENMICOS
SISTEMAS GENMICOS
SISTEMAS GENMICOS
SISTEMAS GENMICOS
SISTEMAS GENMICOS
SISTEMAS GENMICOS
VENTER PHARMA
Vivia Biotech
Biomedal
IMMUNOSTEP
PANGAEA BIOTECH
Progenika Biopharma
ADVANCED MARKER DISCOVERY (Amadix)
ALTHIA
ALTHIA
ALTHIA
Biocross
Biokit S.A
Biokit S.A
Biokit S.A
Biokit S.A
Biokit S.A
Biokit S.A
Biokit S.A
CYTOGNOS
Fundacion MEDINA
Fundacion MEDINA
Gendiag
IMMUNOSTEP
IRYCIS
IRYCIS/F. Hospital Clnico San Carlos
Myriad Genetics
Myriad Genetics
Myriad Genetics
Myriad Genetics
OWL Diagnostics
OWL Diagnostics
OWL Diagnostics
PANGAEA BIOTECH
PANGAEA BIOTECH
Progenika Biopharma
SISTEMAS GENMICOS
Vivia Biotech
Vivia Biotech
Vivia Biotech
ALTHIA
APTUS Biotech
BIOEF - H. Univ. Donostia/BIODONOSTIA
BIOEF - H. Univ.Cruces/BIOCRUCES UPV/EHU
BIOEF - Hospital Universitario Araba/BIOARABA
Biokit S.A
Biokit S.A
FUNDACIN JIMNEZ DAZ (Instituto de Investigacin Sanitaria)
GENOMICA
IMMUNOSTEP
Leitat
Leitat
Leitat
Life Length
Thrombotargets
ALTHIA
ALTHIA
APTUS Biotech
BIOEF - Hospital Universitario Donostia/BIODONOSTIA
Neuropharmagen
HD-Gen test
MitoSeq
WMicroSeq
PancSeq
OvaSeq
ColonSeq
BreastSeq
HC-Gen Test
Kit ABtest40 / 17 / 42
Act-t4 Cell Kit
EPICUP (FAB-115)
In vitro tests for toxicity, safety, ADME and plasma efficacy
Genetic diagnosis of inherited cardiovascular diseases
Clinical exome
Biomarkers toidentify IFN-BETA drug response in multiple sclerosis
Ready-to-use transport kits for xenobiotic interaction studies
Telomere Analysis Technology (TAT Test)
Vectra DA
Alz Test
Simple GDH
Owl Liver NAFLD
OWLiver Care
OWLiver Test
OWLSkin
GENOTYPING
DNA SEQUENCING
MRisk
NeuroGeneProfile
OTOGeneProfile
ONCOGeneProfile
Inmutest
Nuevo CardioGeneProfile
MamaGeneProfile
Oncopharma GeneProfile
GeneSGKits
BabyTest Plus
DI GeneProfile
Onco-GeneSGKits
OSTEOGeneProfile
LacTEST 2,7 powder for oral solution
Personalized Medicine Test in Haematological Malignancies
iVYLISA GIP
Infiltration in CNS
EGFR serum mutation test
ID XT
Personalized Medicine
Multiparametric test
BIO-FLASH HIV-1+2 Ag/Ab
BIO-FLASH anti-HBe
BIO-FLASH HBe Ag
BIO-FLASH VZV IgG and IgM
BIO-FLASH Mumps IgG
BIO-FLASH Measles IgG
BIO-FLASH HSV 1+2 IgM
Diagnosis and MRD Euroflow tubes
FISEVI-62 Diagnotic Image Analisis tool
GENYO-1 Circultaing Biomarkers
FIMABIS-80 Multiple Sclerosis Diagnostic Kit
FISEVI-14017
FISEVI-14001
FISEVI-13008
FISEVI-133
FIBAO-13039
FISEVI-120
FISEVI-13004/13005
Metabolomics Biomarkers Identification Platform
Biomarkers Platform
Familial Hypercholesterolemia
Hemodilucin (Bmplex)
Noverl biomarkers of acute kidney injury based on miRNAs
Biomarkers immunotherapy treatment
myPlan Renal Cancer
myChoice HRD
myPath Melanoma
myPlan Lung Cancer
Neurowlics EM
Owl Liver Fibrosis
Owl Liver ASH
BRCA1 RNA test
EGFR enrichment test
Promonitor
EPILEPSY-GeneProfile
ProstatePredict
Apta-Leish
Predictor of PML
Diagnosis and prognosis of melanoma
Predictor of good response in FEP
BIO-FLASH EBV
HTLV Ab
FIBAO-92-93-122-130-141/FISEVI-124-125-133
FIBICO-14008
FIBAO-14007
FISEVI-121
GENYO-13001 / FIMABIS-13009
FIMABIS-14007
FIMABIS-14005
FIBICO-45
FIMABIS-94
FIBAO-85 Acute Kidney Injury Diagnostic Kit
New kit for detection and quantification of Sin a1 (Yellow mustard)
NEDXA
Disposable device for leukocyte separation
ELISA kit to detect biomarker levels (S100A7)
ELISA kit to detect biomarker levels (S100P)
ELISA kit to detect biomarker levels (S100A4)
qPCR
Diagnosis sensor
mAb for diagnosis and prognosis of brain tumors and lesions
AptaDetect-HCV
Genetic diagnostic based on pooled DNA
Biomarkers
Biomarkers / Diagnostic
Others
Biomarkers
Biomarkers
Diagnostic
Diagnostic/Imaging
Diagnostic
Diagnostic
Others
Biomarkers
Diagnostic/Imaging
Biomarkers
Biomarkers
Diagnostic/Imaging
Diagnostic/Imaging
Biomarkers
Biomarkers
Biomarkers
Biomarkers
Biomarkers
Biomarkers
Biomarkers
Diagnostic
Diagnostic
Biomarkers
Diagnostic
Diagnostic
Others
Diagnostic
Biomarkers
Diagnostic
Biomarkers
Biomarkers
Biomarkers
Patient monitoring equipment
Biomarkers
Biomarkers
Diagnostic
Diagnostic
Diagnostic
Diagnostic
Diagnostic
Diagnostic
Diagnostic
Diagnostic/Imaging
Biomarkers
Biomarkers
Diagnostic/Imaging
Biomarkers
Biomarkers
Biomarkers
Biomarkers
Diagnostic/Imaging
Biomarkers
Diagnostic
Diagnostic
Diagnostic/Imaging
Diagnostic/Imaging
Diagnostic/Imaging
Biomarkers
Biomarkers
Patient monitoring equipment
Diagnostic
Biomarkers
Biomarkers
Biomarkers
Diagnostic
Diagnostic
Biomarkers
Biomarkers
Others
Biomarkers
Diagnostic/Imaging
Biomarkers
Biomarkers
Biomarkers
Biomarkers
Diagnostic
Diagnostic/Imaging
Diagnostic
Diagnostic
Biomarkers
Diagnostic
Diagnostic

Cancer
Infections
Cancer
Cancer
Cancer
Cancer
Cancer
Autoimmune & Inflammation / Infections / Others
Cancer
Others
Cardiovascular and circulatory systems / Genetic Diseases and Dysmorphic syndromes
Others
Cancer / Cardiovascular and circulatory systems
Digestive System / Infections
Digestive System
Digestive System
Digestive System
Dermatology
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Infections
Infections
Infections
Infections
Infections
Infections
Infections
Digestive System
Cancer
Cancer
Cancer
Cancer
Infections
Genetic Diseases and Dysmorphic syndromes / Musculoskeletal Disorders
Infections
Cancer / Infections / Metabolic / Endocrinology
Cancer
Autoimmune & Inflammation / Others
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Infections
Cancer
Infections
Infections
Cancer
Cancer
Cancer
Cancer
Others
Autoimmune & Inflammation / Blood and Lymphatic systems
Cancer / Cardiovascular and circulatory systems
Cancer / Central Nervous System
Infections
BIOHOPE
Immunosuppresors/Immunomodulators in vitro bioassay
BIOHOPE
Biokit S.A
Biokit S.A
CYTOGNOS
CYTOGNOS
CYTOGNOS
CYTOGNOS
FECYT
FERRER
FUNDACIN JIMNEZ DAZ (Instituto de Investigacin Sanitaria)
GENOMICA
GENOMICA
IMEGEN
INBIOMOTION
Leitat
Leitat
Leitat
Merck / Sysmex Inostics
OPERON
OPERON
OPERON
OPERON
PANGAEA BIOTECH
Diagnostic software rejection/tolerance

BIO-FLASH HAV
BIO-FLASH Parvovirus
Diagnosis flow cytometry kit
Euroflow PID tubes
Diagnosis
EPIBREAST (FAB-118)
FIBAO-15012
CABIMER-13001 Trombosis risk biomarker
FIBAO-13005
FIMABIS-15003
CABIMER-13002 Kit for hepatic fibrosis and cirrhosis diagnosis
CABIMER-15004
FIBICO-14009
FIBICO-14025
FIBICO-14025
FIBICO 14008
FIBICO-14001
FIBICO-15015
FIBAO-14010
FIBICO-15013
FIBAO-13004
FIBICO-15012
FIBAO-144/ 13019
FIBAO-15004/ FIBAO14021
FIBAO-13004
FIBAO-13040
FIBAO-13038 / FIBICO-13007
FIBAO-14020
FIBICO-15013
FIBAO-13005
CABIMER-15004
Kit for Diagnosis and Prognosis
CLART CMA ALKROS1
CLART Pneumovir 2
NGS diagnostic Kits
OSTEOMET
Tailored-made formulations with nanoencapsulated active compounds
Metabolic profile
In vitro cellular model for diagnosis
Liquid Biopsy RAS Biomarker Testing
Simple Calprotectin
CT Oligogen
MG Oligogen
NG Oligogen
DX multiplex Non invasive
Treatment prediction system for advanced tumors
POC system based on detection of circulating biomarkers
Diagnostic
Diagnostic
Diagnostic/Imaging
Diagnostic
Diagnostic
Diagnostic/Imaging
Diagnostic
Biomarkers
Biomarkers
Biomarkers
Biomarkers
Biomarkers
Biomarkers
Biomarkers
Diagnostic
Diagnostic
Diagnostic
Diagnostic
Biomarkers
Biomarkers
Diagnostic
Biomarkers
Biomarkers
Biomarkers
Diagnostic
Biomarkers
Others
Biomarkers
Diagnostic
Diagnostic
Biomarkers
Biomarkers
Biomarkers
Diagnostic
Diagnostic
Biomarkers
Others
Biomarkers
Biomarkers
Diagnostic
Diagnostic/Imaging
Diagnostic

Infections
Infections
Infections
Cancer
Infections
Cancer
Cancer
Digestive System
Infections
Infections
Cancer
Cancer
Cancer
Infections
Cancer
Cancer
Infections
Cancer
Digestive System
Cancer
Infections
Infections
Cancer
Cancer
Cancer
Infections
Infections
Digestive System
Infections
Infections
Infections
Cancer
Cancer
Cancer
Pharmacogenetic test to identify the most suitable medication for each neuropsychiatric patient
NGS targeted panel for Hereditary Diseases Test
Whole Mitochondrial Sequencing
Whole Bacterial and Viral Genome Sequencing
Pancreatic cancer NGS genetic test
Ovarian and Breast Cancer NGS genetic test
Colon Cancer NGS genetic test
Breast Cancer NGS genetic test
Hereditary Cancer NGS genetic test
Alzheimers disease diagnostic kit in the early stages
Antibody kit for the identification and quantification by flow cytometry of activated CD4 T-cells
Cancer of Unkown Primary
Cytotoxicity, Neurotoxicity, Mitochondrial Toxicity, Cardiotoxicity, ADME tox
Cardiovascular Diseases
Exome sequencing clinically customized
New patented method to identify good responders to Interferon beta (INF-beta) therapy in multiple sclerosis before treatment initiation
To identify xenobiotic interactions for regulatory purposes
Age related diseases, Cancer, Cardiovascular, Degenerative diseases
Multi-biomarker blood test validated to measure Rheumatoid Arthritis
Discriminatory diagnostic tool between Alzheimers disease and Mild cognitive impairment
One-step immunochromatographic test for the qualitative detection of GDH from C. difficile in human faeces
Non Alcoholic Fatty Liver Disease
Hepatic Diseases, Non-alcoholic fatty liver disease (NAFLD)
Hepatic Diseases, Non-alcoholic fatty liver disease (NAFLD)
Dermatitis and other skin diseases
Genetic risk for Age related Macular Degeneration
Genetic Diagnosis
Melanoma
Neurological diseases
Hearing Impairment
Oncology
Food intolerance
Cardiovascular Risk
Breast Ovarian cancer
136 genes established as biomarkers for the toxicity and response to the most common drugs in Oncology
Kit for capture and sequencing of genes from DNA with CE
For pregnants
Paediatrics
Hereditary cancer
Osteodisplasias and collagenopathies
Subject with lactose intolerance
Acute Myeloid Leukaemia
Monitoring of the gluten free diet in celiac patients
Detection of Leptomeningeal disease
Lung cancer, EGFR mutated
Blood group genotyping
Prostate cancer prognostic test
Colon Cancer prognostic and predictive test
Lung Cancer prognostic and predictive test
Colon Cancer: diagnostic test
Expert system for breast and colon cancer patient management
Patient stratification in glioma
Patient stratification for difuse large b-cell lymphoma therapy
Alzheimers disease
HIV
Haepatitis B
Haepatitis B
Varicella
Mumps
Measles
Herpes 1 and Herpes 2
Multiple Myeloma patients by flow cytometry
Fibrosis / NASH (non-alcoholic steatoHaepatitis)
Metastasis
Multiple sclerosis
Parkinsons disease and other parkinsonims
Endometrial carcinoma
Colorectal cancer
Chronis obstructive respiratory disease / Lung cancer (adenocarcinoma)
Haepatitis C
Duchenne muscular dystrophy (DMD) and others
Haepatitis C
Cancer Infectious Metabolism and Infectious Biomarkers
Lung Colon Breast Pancreas
Diagnosis of Familial Hypercholesterolemia by means of detecting any variant (SNPs) present in the genes clearly involved in causing FH.
Detection of hemodilution in bone marrow samples
The identified panel of miRNAs can detect acute kidney injury (AKI) development before serum creatinine increases
Biomarkers based on IgE profile for determining oral immunotherapy treatment response in children with cows milk protein allergy
Test Prognostics for renal cancer
Companion diagnostic test to identify metastatic breast cancer, ovarian and other tumor types that may be sensitive to iPAPR and/or platinum
Genetic profile to test pathogenic status of Melanoma biopsy
Lung Cancer prognostic test based on Cell Cycle Progression Genes
Multiple sclerosis prognosis
Liver Fibrosis
Alcoholic esteatoHaepatitis
Solid tumours
Lung cancer, EGFR mutated
Monitoring of biologics
Next-Generation Sequencing panel of 352 genes associated with epilepsy of family origin
Chronic Lymphocytic Leukaemia
Multiple Myeloma
Acute Lymphocytic Leukaemia
Diagnostic and Prognostic biomarkers for prostate cancer
Leishmaniasis
Predictor of the risk of developing progressive multifocal leucoencephalopathy in natalizumab-treated multiple sclerosis patients
Diagnosis and Prognosis of melanoma
Future good response to antipsychotic drugs in first-episode psychosis (FEP) disorders
Epstein-Barr Virus Infection
Human T-lymphotropic virus infection
Adenocarcinome, Breast, Lung, Colorectal, Cervix tumours and Pancreas cancer / 5-FU treatment Prognosis
Lung cancer screening
Circulating stem cells
Transplant
Lupus erythematosus / Allergy
Allergic rhinitis
Breast cancer
Vascular Calcification
Acute Lymphoblastic Laeukemia (ALL)
Acute Renal Failure
Food Mustard Allergy
Point of Care instrument/ Lab on a Chip
Hematological malignancies
Diagnosis and prognosis of several cancers
Diagnosis and prognosis of Pancreatic cancer, colon cancer, others
Diagnosis and prognosis of Pancreatic cancer, colon cancer, others
Age related diseases, Cancer, Cardiovascular, Degenerative diseases
Alzheimer Disease
Biomarker for Gastric cancer
Glioblastoma, neurodegenerative disease
Haepatitis C Virus (HCV)
Genetic diagnostic based on pooled DNA
Renal Transplant: immunomodulation, immunosuppresion, tolerance induction. This bioassay helps define the best treatment combination possible for a
certain patient to control rejection and avoid over immunosuppresion
Renal Transplant. Stratification of transplanted patients according to their immunological response
Haepatitis A
Parvovirus infection
Diagnosis and follow-up of influenza, tuberculosis, Haepatitis C and HIV
Diagnosis and follow-up of allergies (Type I Hypersensitivity)
Antibody kit for the diagnosis of immunodeficiencies by flow cytometry
Multiple Myeloma, Non-Hodgkin Lymphoma and Glioma
Malaria
Breast Cancer
Meniere Disease
Mesenchymal Stem Cells (MSCs)
Colon Cancer
Diabetes / metabolic diseases
Hepatic Fibrosis and Cirrhosis
Amyotrophic Lateral Sclerosis
Haepatitis C
Haepatitis C
Lung cancer
Hepatocarcinoma diagnosis
lung cancer
Meniere Disease
Systemic infection
Colon Cancer
prostate
Meniere Disease
Diagnostic Kit Haepatitis C
Colon Cancer
Anastomosis
Cancer / Treatment of angiogenesis
Haepatitis C
Systemic infection
Colon Cancer
AMYOTROPHIC LATERAL SCLEROSIS
Chronic Kidney Disease (CKD)
Kit for detection of gene mutations involved in responses to anti-tumour therapy in NSC Lung Cancer
Detection of viruses causing respiratory diseases
Ready to use customized kits for using in NGS platforms
Breast and Prostate cancer
Atopic dermatitis, psoriasis
Helicobacter pylori infection, oxidative stress
Helicobacter pylori virulence
Metastatic colorectal cancer
One-step immunochromatographic test for the qualitative detection of Calprotectin in human faeces
Genetic test designed for the detection of Chlamydia trachomatis
Test designed for the detection ofMycoplasma genitalium
Test designed for the detection ofNeisseria goorrhoeae
Various tumours
Multiple cancers
Colon cancer
R+D
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
Preliminar
Validation
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
Clinical
Validation
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
Register
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
Ready To
Market
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
Studies Location
Spain
Spain
Spain
Spain
Spain
Spain
Spain
Spain
Worldwide
Spain
Europe
Spain
Europe, Middle East, North
America and Latinamerica
Spain
Europe
Europe
Spain
Worldwide
USA and Canada
Europa and America
Europe
Worldwide
Worldwide
Worldwide
Worldwide
Worldwide
Worldwide
Worldwide
Worldwide
Worldwide
Worldwide
Worldwide
Worldwide
Worldwide
Worldwide
Worldwide
Europe
Spain
Worldwide
Worldwide
Spain
Spain
Spain
Spain
Spain
Spain
Spain
Europe
Spain
Europe
Europe
Europe
Europe
Europe
Europe
Europe
Europe
Europe
Spain
Spain
Spain, Portugal and Chile
Worldwide
Spain
Spain
Worldwide
Worldwide
Worldwide
Europe
Europe
Europe
Worldwide
Worldwide
Worldwide
Europe
Europe
Europe
Spain
Spain
Europe
Europe
Europe
Europe
Europe
Europe
Spain
Spain
Spain
Spain
Spain
Spain
Europe
Spain
Spain
Spain
<<<<<
Spain
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
Spain
Australia and Europe
Europe
Spain
Europe
Europe
europe
Spain
Europe
Europe
Spain
Spain
Spain
Spain
Worldwide
Spain
Spain
Spain
Spain
Spain
Europe
Spain
Spain and Germany
OTHER TECHNOLOGIES
Company
BTI Biotechnology Institute
IRYCIS
IRYCIS/UC3M
Reig Jofr
Stem Center S.L.U.
Histocell
IRYCIS
IRYCIS
PRAXIS
PRAXIS
Product
PRGF-Endoret Technology
GENYO-13002 Lentiviral Systems
Medical Device for alopecia monitoring
Biopsypunch
Blox Allergy
GID System
Reoxcare
FIBAO-47
FIBAO-13031
FIBAO-15011
FIBAO-14018
Smartphone-based platform for teledermatology
Virtual reality and cognitive rehabitlitation
POLYHEAL
Kit-Chagas
Type
Biomaterials & Tissue Therapy
Others
Medical devices
Medical devices
Medical devices
Medical devices
Medical devices
Others
Others
Others
Diagnostic
Others
Others
Medical devices
Medical devices
BIOIMAG
Magnetically Functionalized Collagen
BTI Biotechnology Institute
PRGF-Endoret Technology
GENYO-13007 MSCs Biomarker
GENYO-13006
FISEVI-140
FIBAO-15014
FUND. Progreso y salud/ FIMABIS / OTT (SAS)
FIMABIS-15004
FUNDACIN JIMNEZ DAZ (Instituto de Investigacin Sanitaria) Titanium materials anodised with fluorine
FUNDACIN JIMNEZ DAZ (Instituto de Investigacin Sanitaria) Osteoblast-enriched bone allograft
Histocell
HR007
IRYCIS
Telemedicine platfroms

Others
Others
Medical devices
Tissue Therapy
Others
ALGENEX (Alternative Gene Expression S.L.)

CrisBio
GENYO-13008
LARCEL-14001
CABIMER-13005 Culture Medium and Biomaterial
FIBICO 14014
CABIMER-13004 Culture Medium
FIBICO 13003
FIBAO-13024
FIBAO-13028
FIBAO-15019
FIBAO-106
FIBAO-124
FIBICO 14014
FIBICO 13003
FUNDACIN JIMNEZ DAZ (Instituto de Investigacin Sanitaria) Materials with controlled-release of bioactive agents
FUNDACIN JIMNEZ DAZ (Instituto de Investigacin Sanitaria) Osteostatin-based biomaterial
IRYCIS
New software for interpretation of renal ultrasound images
Others
Others
Others
Others
Medical devices
Medical devices
Medical devices
Others
Others
Therapy
Therapy monitoring
Others
Therapeutic Area
Dental / Dermatology / Musculoskeletal Disorders / Ophthalmology and optometry
Others
Dermatology
Dermatology
Others
Dermatology
Others
Others
Others
Others
Dermatology
Dermatology
Others
Autoimmune & Inflammation / Cancer / Cardiovascular and circulatory systems / Central
Nervous System / Dental / Dermatology / Musculoskeletal Disorders / Others
Others
Others
Dental
Infections
Analgesia & Pain
Analgesia & Pain
Dermatology
Cancer / Others
Others
Others
Infections
Others
Others
Others
Others
Indication
Biomedical technology focused on stimulating tissue healing and regeneration through the application of growth factors and other proteins that are present in plasma.
Insulator for improve gene expression
Medical device for a standarized monitoring of alopecia
New device for dermatological biopsies
Avoiding allergens
Plastic and reconstructive surgery
Wound healing
Cardiovascular and circulatory system
Urinary Tract Infections
Application for tablets and phones
Cardiovascular diseases
Communication channel between primary care physicians and dermatologists
virtual realitity for rehabilitation of patitients with heminegligencies
Bioactive wound dressings (Diabetic / vascular)
Chagas
R+D
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
Preliminary
Validation
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
For the monitoring of the remodeling of the extracellular matrix and implants. Diagnostic agent designed to be used in regenerative therapies and tissue engineering
Ophthalmology
Surface marker for MSCs
Multipotent Mesenchimal Stroma Cells Subpopulation
Resorbable membrane for guided bone regeneration
Sampling of bacterial flora
Method for selection of replacement tissues, urethra regeneration
New material with antibacterial properties
Spinal fusion
Tissular Regeneration
Comprehensive management of upper lymphedema after breast cancer, including its early detection, a practical-theoretical training and the possibility of contact with the
specialist
Technology platform to produce recombinant proteins for use in diagnostics or vaccine development using insect pupae as a host with BEVS
Method for obtaining megakaryocytes and platelets
Method for generating Induced Pluripotent Stem Cells (iPSC)
Mesothelial cells in Tissue Bioengineering
Blepharitis, dry eye syndrom, various opthtalmologic diseases.
Xeno-free culture and differentiation medium to convert hPSC to neural progenitors
Angiogenesis
Sterility three-way stopcoks and tube connectors.
Double serum bag
Bioconector
Refractoriness predictive model of temporal lobe epilepsy
Manual for use of the software application to help Clinical Management Units (CMU)
Blepharitis, dry eye syndrom, various opthtalmologic diseases
Angiogenesis
Osteomyelitis (Bone implants)
Bone regeneration and Tissue engineering
Software for interpretate ultrasound renal images by a non specialist in ultrasound
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
* Based on data provided by ASEBIO members. MAY 2015. ** Only coloured phases have been developed in Spain
www.asebio.com
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
Clinical
Validation
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
Register
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
Ready
To Market
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
<<<<<
Studies Location
Europe
Spain
Spain
Spain
Europe
Spain
Spain
Spain
Spain
Europe
EU/USA/LA
Spain, US ( CCMIJU,
ICP-CSIC, BWH, HMS)
Europe
Spain
Spain
Spain
Europe
Spain
Spain
Spain
Spain
Spain
Spain
Spain

Spanish Red Biotech Pipeline 2016

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Spanish Red Biotech Pipeline 2016

Uploaded by

Copyright:

Available Formats

Spanish Red Biotech Pipeline